JP2024540044A5 - - Google Patents
Info
- Publication number
- JP2024540044A5 JP2024540044A5 JP2024525160A JP2024525160A JP2024540044A5 JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5 JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024525160 A JP2024525160 A JP 2024525160A JP 2024540044 A5 JP2024540044 A5 JP 2024540044A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- cycle
- mosnetuzumab
- day
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025155232A JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2021/057439 WO2023075798A1 (en) | 2021-10-29 | 2021-10-29 | Methods for treatment of relapsed/refractory follicular lymphoma with mosunetuzumab and lenalidomide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155232A Division JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024540044A JP2024540044A (ja) | 2024-10-31 |
| JP2024540044A5 true JP2024540044A5 (https=) | 2025-05-20 |
| JP7846761B2 JP7846761B2 (ja) | 2026-04-15 |
Family
ID=86158448
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525160A Active JP7846761B2 (ja) | 2021-10-29 | 2021-10-29 | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 |
| JP2025155232A Pending JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025155232A Pending JP2026004356A (ja) | 2021-10-29 | 2025-09-18 | モスネツズマブおよびレナリドミドを用いた再発性／難治性濾胞性リンパ腫の処置方法 |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JP7846761B2 (https=) |
| KR (1) | KR20240093915A (https=) |
| AU (1) | AU2021471006A1 (https=) |
| CA (1) | CA3236111A1 (https=) |
| MX (1) | MX2024005105A (https=) |
| PE (1) | PE20241211A1 (https=) |
| WO (1) | WO2023075798A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026009843A (ja) * | 2024-06-25 | 2026-01-21 | ジェネンテック， インコーポレイテッド | 単剤療法としてまたはレナリドミドと組み合わせたモスネツズマブの皮下投与を用いてがんを処置する方法 |
| WO2026050474A1 (en) * | 2024-08-28 | 2026-03-05 | Genentech, Inc. | Subcutaneous dosing of mosunetuzumab in combination with polatuzumab vedotin for use in treating non-hodgkin's lymphoma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020275415B2 (en) * | 2019-05-14 | 2026-01-15 | Genentech, Inc. | Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma |
-
2021
- 2021-10-29 JP JP2024525160A patent/JP7846761B2/ja active Active
- 2021-10-29 CA CA3236111A patent/CA3236111A1/en active Pending
- 2021-10-29 AU AU2021471006A patent/AU2021471006A1/en active Pending
- 2021-10-29 WO PCT/US2021/057439 patent/WO2023075798A1/en not_active Ceased
- 2021-10-29 MX MX2024005105A patent/MX2024005105A/es unknown
- 2021-10-29 PE PE2024000932A patent/PE20241211A1/es unknown
- 2021-10-29 KR KR1020247017366A patent/KR20240093915A/ko active Pending
-
2025
- 2025-09-18 JP JP2025155232A patent/JP2026004356A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3076972B1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| US8618083B2 (en) | Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer | |
| JP2024015120A5 (https=) | ||
| CN117956995A (zh) | 一种ezh2抑制剂用于制备治疗t细胞淋巴瘤的药物的用途 | |
| WO2012072505A1 (en) | Volasertib alone or in combination with cytarabine for treating acute myeloid leukemia | |
| JP2024530189A5 (https=) | ||
| JP2020516646A5 (https=) | ||
| WO2022218958A1 (en) | Combination comprising everolimus and amcenestrant | |
| JP2015500822A5 (https=) | ||
| JP2025509510A5 (https=) | ||
| JP2019508476A5 (https=) | ||
| JP2022544485A5 (https=) | ||
| JP2023516951A (ja) | アルペリシブおよび６－（２，４－ジクロロフェニル）－５－［４－［（３ｓ）－１－（３－フルオロプロピル）ピロリジン－３－イル］オキシフェニル］－８，９－ジヒドロ－７ｈ－ベンゾ［７］アヌレン－２－カルボン酸を含む組合せ物 | |
| JP2024540044A5 (https=) | ||
| JP2010538066A5 (https=) | ||
| JP2022523530A5 (https=) | ||
| JP2024517085A5 (https=) | ||
| JP2024539476A5 (https=) | ||
| JP2023011549A5 (https=) | ||
| Paszkiewicz-Kozik et al. | Early efficacy and safety of obinutuzumab with chemotherapy in previously untreated patients with follicular lymphoma: A real-world retrospective report of the Polish Lymphoma Research Group | |
| JP2022058873A5 (https=) | ||
| JP2024506385A5 (https=) | ||
| RU2485956C2 (ru) | Новая композиция для лечения побочных эффектов противораковой терапии | |
| JP2025521501A5 (https=) | ||
| WO2025044079A1 (zh) | 一种act001组合物的抗肿瘤用途 |